114 related articles for article (PubMed ID: 38520670)
1. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Greengard E; Williams R; Moriarity B; Liu X; Minard CG; Reid JM; Fisher T; Evans E; Pastore DR; Zauderer M; Voss S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2024 Jun; 71(6):e30938. PubMed ID: 38520670
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
8. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Shafique MR; Fisher TL; Evans EE; Leonard JE; Pastore DRE; Mallow CL; Smith E; Mishra V; Schröder A; Chin KM; Beck JT; Baumgart MA; Govindan R; Gabrail NY; Spira AI; Seetharamu N; Lou Y; Mansfield AS; Sanborn RE; Goldman JW; Zauderer M
Clin Cancer Res; 2021 Jul; 27(13):3630-3640. PubMed ID: 33820783
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
10. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI; Fox E; Turpin BK; Goldstein SL; Liu X; Minard CG; Kudgus RA; Reid JM; Berg SL; Weigel BJ
Cancer; 2018 Dec; 124(23):4548-4555. PubMed ID: 30394521
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
13. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.
Bishop MW; Hutson PR; Hank JA; Sondel PM; Furman WL; Meagher MM; Navid F; Santana VM
MAbs; 2020; 12(1):1773751. PubMed ID: 32643524
[TBL] [Abstract][Full Text] [Related]
17. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
